Coverage
-
January 23, 2018
The Federal Circuit on Tuesday upheld a Patent Trial and Appeal Board decision invalidating a Johnson & Johnson patent on the blockbuster autoimmune disease drug Remicade for double patenting, in a win for Pfizer Inc., which launched a biosimilar version in 2016.
1 other articles on this case.
View all »